INT262585

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 1.08
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (Renbp)
Anatomy Link Frequency
body 1
Renbp (Mus musculus)
Pain Link Frequency Relevance Heat
Glutamate 87 5.00 Very Low Very Low Very Low
ischemia 36 5.00 Very Low Very Low Very Low
nMDA receptor 27 5.00 Very Low Very Low Very Low
Glutamate receptor 18 5.00 Very Low Very Low Very Low
antagonist 15 5.00 Very Low Very Low Very Low
Neurotransmitter 15 5.00 Very Low Very Low Very Low
Central nervous system 6 5.00 Very Low Very Low Very Low
gABA 6 5.00 Very Low Very Low Very Low
carbamazepine 6 5.00 Very Low Very Low Very Low
GABA receptor 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 39 98.96 Very High Very High Very High
Renal Disease 3 98.04 Very High Very High Very High
Diabetic Angiopathy 3 97.88 Very High Very High Very High
Renal Failure 3 93.12 High High
Toxicity 3 65.76 Quite High
Neurodegenerative Disease 15 50.00 Quite Low
Apoptosis 117 45.76 Quite Low
Metabolic Disorder 6 44.68 Quite Low
Disease 27 39.76 Quite Low
Age-related Macular Degeneration 24 16.56 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Likewise, the use of the AGE binding properties of lysozyme has succeeded in reducing AGE levels in dialysate from diabetic patients with kidney disease [110] and presents a real possibility for reduction of toxic AGE groups in the body fluids of patients with renal failure.
Negative_regulation (reducing) of AGE in body associated with renal failure, diabetes mellitus and renal disease
1) Confidence 0.01 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647152 Disease Relevance 0.44 Pain Relevance 0
In the experimental animal, AGE effects could be significantly reversed by the pharmacological AGE inhibitor aminoguanidine [189].
Negative_regulation (reversed) of AGE
2) Confidence 0.01 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647152 Disease Relevance 0.40 Pain Relevance 0
This drug can prevent some diabetic vascular complications in experimental animals, [24, 55, 133] while clinical trials of aminoguanidine were shown to effectively reduce AGE-Hb while leaving HbA1c unaffected [17].
Negative_regulation (reduce) of AGE associated with diabetic angiopathy
3) Confidence 0.01 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647152 Disease Relevance 0.23 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox